Heart Disease Often Begins Long Before The First Heart Attack

Most people do not spend much time thinking about their cholesterol levels on a day-to-day basis. In fact, many individuals feel completely healthy until a sudden medical emergency forces them to pay attention.

For more than one million Americans each year, that emergency comes in the form of acute coronary syndrome (ACS) — a term that includes both heart attacks and unstable angina. While these conditions have significant differences, they share a common cause: reduced blood flow to the heart.

What is Acute Coronary Syndrome?

Acute coronary syndrome occurs when blood flow through the coronary arteries — the blood vessels that supply the heart muscle — becomes severely limited. This reduction in blood flow, known as ischemia, is most often caused by atherosclerosis, a gradual buildup of cholesterol-rich plaque and inflammation within the artery walls.

Over time, these plaques narrow the arteries, making it increasingly difficult for oxygen-rich blood to reach the heart. For years, this process may develop silently without causing any symptoms. Eventually, however, the narrowing can become severe enough that the heart's blood supply can no longer meet its needs.

When this happens, symptoms often appear suddenly and may include chest pain or pressure, shortness of breath, nausea, sweating, unusual fatigue, or discomfort that radiates to the jaw, neck, back, or arm. Without prompt medical attention, permanent damage to the heart and other organs can occur.

Why Does Heart Disease Often Go Undetected?

One of the challenges of coronary artery disease is slow asymptomatic nature with which it progresses as cholesterol buildup develops gradually over many years, often without warning signs. For many patients, a heart attack or episode of unstable angina is the first indication that significant heart disease has been developing beneath the surface. While this process of dyslipidemia has long stood as an independent modifiable risk factor for developing heart disease accompanied by others including smoking, diabetes, and hypertension (Standard Modifiable Risk Factors or SMuRFs) research has shown that upwards of 20% of patients who suffer a heart attack or develop heart disease are without any of these. This invisible paradox highlights the continued need for early detection, prevention, and intervention further ongoing with expansion of additional risk factor research with novel biological markers and less traditional conditions like underlying inflammation.

Decades of dedicated research and innovation have led to new medications and therapeutic interventions which have significantly improved mortality for ACS patients. Unfortunately, surviving an initial ACS event is only the beginning of recovery and patients face a litany of short- and long-term complications and increased risks. Research suggests that approximately one in five patients will experience another ACS event within nine years of their first. These individuals also experience elevated rates of heart failure, kidney complications, and even psychological conditions such as depression and post-traumatic stress disorder. As a result, ischemic heart disease remains one of the leading causes of death worldwide and continues to represent a major public health challenge.

How Are New Discoveries Changing Prevention and Treatment?

Fortunately, ongoing research has significantly improved our understanding of cholesterol, atherosclerosis, and cardiovascular risk. These advances have led to the development of new medications and treatment strategies designed to prevent heart attacks before they occur and reduce the likelihood of recurrence in patients who have already been affected.

Earlier in 2026, experts from the American College of Cardiology and the American Heart Association released updated clinical practice guidelines reflecting many of these advances. One notable change was a broader focus on "dyslipidemia" rather than simply cholesterol management, recognizing that cardiovascular risk involves more than just total cholesterol and LDL ("bad cholesterol") levels.

The updated recommendations place greater emphasis on early identification and treatment of risk factors, reinforcing the importance of prevention long before symptoms develop. For patients with established heart disease, the guidelines also support more aggressive cholesterol-lowering strategies, including lower LDL targets and, in some cases, early initiation of combination therapy.

In addition, growing evidence has increased interest in advanced lipid testing, including ApoB and Lp(a), which may help identify individuals at elevated cardiovascular risk even when traditional cholesterol measurements appear acceptable. With several major trials in progress actively working on development state-of-the-art medications to aid in improving these inflammatory lipid particles currently without treatment options.

Looking Toward the Future

The publication of the 2026 guidelines represents another major step forward in the prevention and treatment of heart disease. As researchers continue to expand our understanding of atherosclerosis and cardiovascular risk, new therapies and treatment approaches are helping shape the future of patient care. At Chase Medical Research, we are proud to contribute to that future through ongoing clinical trials focused on cardiovascular and metabolic health, including studies involving dyslipidemia and related conditions.

Whether you or a loved one have a history of heart disease, elevated cholesterol, or simply want to learn more about protecting your long-term health, we invite you to contact our office. Our team of expert medical professionals is here to answer your questions and help guide you through available research opportunities.